相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer
Sameer A. Siddiqui et al.
BJU INTERNATIONAL (2011)
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer
Francesco Boccardo et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men With Progressive Castration-Resistant Nonmetastatic Prostate Cancer
Matthew R. Smith et al.
CANCER (2011)
Utilization and Expense of Adjuvant Cancer Therapies Following Radical Prostatectomy
Stephen B. Williams et al.
CANCER (2011)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Small Molecule Inhibitors Targeting the Achilles' Heel of Androgen Receptor Activity
Marianne D. Sadar
CANCER RESEARCH (2011)
Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Medha S. Darshan et al.
CANCER RESEARCH (2011)
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Changmeng Cai et al.
CANCER RESEARCH (2011)
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
Charles J. Ryan et al.
CLINICAL CANCER RESEARCH (2011)
A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!
Zhiyong Guo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2011)
Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment
Vassiliki Tzelepi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Snapshot of the Expression Signature of Androgen Receptor Splicing Variants and Their Distinctive Transcriptional Activities
Rong Hu et al.
PROSTATE (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Targeting Drug-Metabolizing Enzymes for Effective Chemoprevention and Chemotherapy
Hollie I. Swanson et al.
DRUG METABOLISM AND DISPOSITION (2010)
BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
Rong Hu et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2010)
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
B. Mellado et al.
BRITISH JOURNAL OF CANCER (2009)
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway
Begona Mellado et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
Kathy S. Albain et al.
LANCET (2009)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications
Elahe A. Mostaghel et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Targeting the androgen receptor pathway in prostate cancer
Yu Chen et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
Dana Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Eric M. Horwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial
James W. Denham et al.
LANCET ONCOLOGY (2008)
Sintokamides A to E, Chlorinated Peptides from the Sponge Dysidea sp that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells
Marianne D. Sadar et al.
ORGANIC LETTERS (2008)
Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response
Michael Milosevic et al.
CANCER RESEARCH (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
Androgen receptor decoy molecules block the growth of prostate cancer
Steven N. Quayle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
C17,20-lyase inhibitors.: Part 2:: Design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors
N Matsunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Role of secondary hormonal therapy in the management of recurrent prostate cancer
CJ Ryan et al.
UROLOGY (2003)
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy
LH Klotz et al.
JOURNAL OF UROLOGY (2003)
Can older cancer patients tolerate chemotherapy? A prospective pilot study
HB Chen et al.
CANCER (2003)
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02
GE Hanks et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial
G Aus et al.
BJU INTERNATIONAL (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
分享论文
